ReviewCancers2020
Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 148 citations in OpenAlex.
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Photodynamic therapy in head and neck squamous cell carcinoma: immunomodulation and stromal targeting of cancer-associated fibroblasts.Translational oncology · 2026Review
- Review
- MEK inhibitor cobimetinib increases calreticulin and induces immune modulation in TNBC.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Early effects of ionizing radiation on molecular modifications and hallmarks of Immunogenic cell death in mouse tumor cells.BMC cancer · 2026Article
- Genetically Engineered Biomimetic Nanovesicles Co-Deliveing a Checkpoint Inhibitor and Doxorubicin for Enhanced Cancer Chemo-Immunotherapy.Pharmaceutics · 2026Article
- Induction of immunogenic cell death by active components of natural products reshaping the tumor microenvironment for enhanced antitumor immunity.Frontiers in pharmacology · 2026Review
- Investigating the potential role of miR-451a as a tumor suppressor in immunogenic cell death induction and dendritic cell maturation in colorectal cancer cell lines.Cancer cell international · 2025Article
- Immunological Impact of Oncolytic Adenoviruses On Cancer Therapy: Clinical Insights.European journal of immunology · 2025Review
- Copper Oxide Nanorods: Potential Agents against Breast Cancer.ACS applied bio materials · 2025Article
- Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology.Discover nano · 2025Review
- Bioactive metallic nanoparticles for synergistic cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025Review
- Using ultrasound and microbubble to enhance the effects of conventional cancer therapies in clinical settings.Cancer metastasis reviews · 2025Review
- Cross-Talk Between Tumor Cells and Stellate Cells Promotes Oncolytic VSV Activity in Intrahepatic Cholangiocarcinoma.Cancers · 2025Article
- Nano-delivery of Silibinin Potentiate the Induction of Immunogenic Cell Death (ICD) in Melanoma Cells.Current pharmaceutical biotechnology · 2025Article
- Research progress on the cross-regulation between ferroptosis and immunogenic cell death in tumor micro-environment.Frontiers in oncology · 2025Review
- Targeting Hydrogel for Intelligent Recognition and Spatiotemporal Control in Cell-Based Therapeutics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Immune landscape and response to oncolytic virus-based immunotherapy.Frontiers of medicine · 2024Review
- TET1 is a Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Papillary Thyroid Cancer.Biochemical genetics · 2024Article
- Immunogenic cell death related mRNAs associated signature to predict immunotherapeutic response in osteosarcoma.Heliyon · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell death resistance is a key feature of tumor cells. One of the main anticancer therapies is increasing the susceptibility of cells to death. Cancer cells have developed a capability of tumor immune escape. Hence, restoring the immunogenicity of cancer cells can be suggested as an effective approach against cancer. Accumulating evidence proposes that several anticancer agents provoke the release of danger-associated molecular patterns (DAMPs) that are determinants of immunogenicity and stimulate immunogenic cell death (ICD). It has been suggested that ICD inducers are two different types according to their various activities. Here, we review the well-characterized DAMPs and focus on the different types of ICD inducers and recent combination therapies that can augment the immunogenicity of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.